[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100352205":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":23,"collaborators":7,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":37,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Amicus Therapeutics","INDUSTRY",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","ATB200",{"type":13,"name":14,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","AT2221",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"For Site","CONTACT","866-9AMICUS","patientadvocacy@amicusrx.com",{"name":22,"role":18,"phone":19,"phoneExt":7,"email":20},"For Patient",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100352205","expanded-access-for-atb200at2221-for-the-treatment-of-pompe-disease-100352205",false,"NCT03865836","Expanded Access for ATB200\u002FAT2221 for the Treatment of Pompe Disease","Named Patient or Compassionate Use for Treatment Use of ATB200\u002FAT2221 for Patients With Pompe Disease","Inclusion Criteria:\n\n1. Subject must have a diagnosis of Pompe disease based on documentation of one of the following:\n\n   1. deficiency of GAA enzyme\n   2. GAA genotyping\n2. Patient does not currently qualify for an Amicus sponsored on-going clinical trial or is declining on currently approved ERT (e.g. Myozyme)\n3. The patient must be willing to receive treatment with ATB200\u002FAT2221 via this program, which includes signing an authorization form for sharing clinical data with Amicus Therapeutics, and its agent Early Access Care LLC.\n\nExclusion Criteria:\n\n1. Patient, whether male or female, is planning to conceive a child during the treatment program.\n2. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221\n3. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his\u002Fher ability to comply with or adversely impact protocol requirements.\n4. Patient has received any gene therapy at any time.\n5. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb, or Volibo)","ALL","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200\u002FAT2221.",[36],"Pompe Disease",[38,39],"expanded access","compassionate use","AVAILABLE","2025-09-09",{"date":43,"type":44},"2025-09-15","ACTUAL",{"name":5,"class":6}]